Aspen stock holds as Aspen Pharmacare reports fiscal 2025 results

Aspen stock is shaped by Aspen Pharmacare Holdings Limited (ISIN ZAE000066692), which reported fiscal 2025 revenue of ZAR 42.4 billion, normalized EBITDA of ZAR 7.9 billion, and net debt of ZAR 22.1 billion in its latest investor material.

The company also said fiscal 2025 revenue was up 7% on a reported basis, while normalized EBITDA increased 4%, giving investors a dated operating frame as of fiscal 2025.

Fiscal 2025 revenue at ZAR 42.4 billion

Revenue of ZAR 42.4 billion in fiscal 2025 is the central top-line figure, and the 7% year-on-year increase gives the number its main comparison point. Normalized EBITDA of ZAR 7.9 billion and net debt of ZAR 22.1 billion show how earnings and leverage sit alongside sales growth in the same reporting period.

A second comparison matters just as much: normalized EBITDA rose 4% in fiscal 2025, which was slower than the 7% revenue rise and therefore points to a margin mix that investors usually read carefully.

Debt at ZAR 22.1 billion

Net debt of ZAR 22.1 billion remains the clearest balance-sheet marker in the latest set of figures. Measured against fiscal 2025 normalized EBITDA of ZAR 7.9 billion, that gives a simple leverage frame for the period.

The latest numbers also connect to the company narrative around scale, because a ZAR 42.4 billion revenue base, a ZAR 7.9 billion earnings base, and ZAR 22.1 billion of net debt all belong to the same fiscal 2025 update.

Aspen products and cash generation

In its product mix, Aspen Pharma has long relied on a broad portfolio of branded, specialty, and sterile medicines, with the investor material framing the business around commercial execution rather than a single product cycle. That matters because the fiscal 2025 numbers were not only about turnover, but also about how earnings and debt moved together.

For a stock article, the useful point is that the latest figures are dated and comparable: fiscal 2025 revenue of ZAR 42.4 billion, normalized EBITDA of ZAR 7.9 billion, and net debt of ZAR 22.1 billion.

Market value and trading context

The body text focuses on the available fiscal 2025 metrics and the current investor-relations frame. Aspen stock trades on the Johannesburg market under the Aspen Pharmacare listing, and the key valuation backdrop for readers is the same fiscal 2025 set of ZAR 42.4 billion revenue, ZAR 7.9 billion normalized EBITDA, and ZAR 22.1 billion net debt.

As a standalone market reference, the company remains defined here by its latest annual-period numbers rather than a short-term price move.